$CHRS
Coherus Oncology, Inc. Common Stock
XNAS•Health Care•Biological Products, (No Diagnostic Substances)
$1.31
▲+6.20%+$0.076
Subscriptions are live. Early access $24.99/mo, or start with 5 free premium days.
Plans & pricingDonateCoherus Oncology, Inc. Common Stock
XNAS•Health Care•Biological Products, (No Diagnostic Substances)
Why is CHRS up today? It is at $1.31 (+6.20%), and our scanner flagged it 23 times on unusual volume this month. See the catalyst behind the move, real-time alerts the moment CHRS spikes, and full due diligence on CHRS — key stats, earnings, dilution and insider activity. Free.
Our scanner flagged $CHRS 23 times in the last 30 days. Create a free account to track $CHRS, build a watchlist, and get instant unusual-volume alerts, with a full day of premium now and 5 more when you verify your email, no card needed.
No card · 5 premium days · join 800+ traders
The top plays and unusual-volume catches our scanner flags, emailed to you. No account needed.
No spam. Unsubscribe anytime. Not investment advice.
Here is the latest on CHRS from our scanner (live price and day move above). We have not detected an unusual-volume catalyst for CHRS today, so it is trading in line with its recent range. The moment our scanner flags unusual activity, the reason will appear here.
| Insider | Action | Shares | % of position | Owns after | Value | Date |
|---|---|---|---|---|---|---|
Newton Charles W. Director | Acquired (grant/award) | +30K 0.02% of company | n/a | 30K | n/a | Jun 5, 26 |
Wahlstrom Mats Director | Acquired (grant/award) | +30K 0.02% of company | n/a | 30K | n/a | Jun 5, 26 |
O'Donnell-Tormey Jill Director | Acquired (grant/award) | +30K 0.02% of company | n/a | 30K | n/a | Jun 5, 26 |
Ryan Michael Lee Director | Acquired (grant/award) | +30K 0.02% of company | n/a | 30K | n/a | Jun 5, 26 |
Newcomer Lee Nisley Director | Acquired (grant/award) | +30K 0.02% of company | n/a | 30K | n/a | Jun 5, 26 |
Karachun Rita A Director | Acquired (grant/award) | +30K 0.02% of company | n/a | 30K | n/a | Jun 5, 26 |
Satvat Ali J. Director | Acquired (grant/award) | +30K 0.02% of company | n/a | 30K | n/a | Jun 5, 26 |
Lanfear Dennis M Officer | Acquired (grant/award) | +375K 0.2% of company | added 56% | 1.05M | n/a | Jan 23, 26 |
Mcmichael Bryan J Officer | Acquired (grant/award) | +113K 0.07% of company | added 100% | 134K | n/a | Jan 22, 26 |
Lanfear Dennis M Officer | Sold (automatic/other) | -12K | sold 1.7% | 673K | $18K at $1.55 | Jan 20, 26 |
Mcmichael Bryan J Officer | Sold (automatic/other) | -2K | sold 7.5% | 21K | $3K at $1.55 | Jan 20, 26 |
Wahlstrom Mats Director | Sold (automatic/other) | -100K 0.06% of company | n/a | n/a | $74K at $0.740 | May 23, 25 |
Recent Form-4 filings via Nasdaq. Open-market buys are the signal worth watching. Grants and automatic (10b5-1) sells are routine. “% of position” is the share of that insider’s own holding the trade moved. Not investment advice.
Blend of news sentiment, today’s move, and community votes. Not investment advice.
News, unusual-volume alerts, AI-trader trades and community chatter - the whole story, newest first.
Comparable names in biological products, (no diagnostic substances), closest in size first.
Here is the latest on CHRS from our scanner (live price and day move above). We have not detected an unusual-volume catalyst for CHRS today, so it is trading in line with its recent range. The moment our scanner flags unusual activity, the reason will appear here.
CHRS last traded at $1.31, up 6.20% on the day. The price and chart above update live during market hours (4 AM to 8 PM ET).
Coherus Oncology, Inc. Common Stock (CHRS) is next expected to report earnings on Thursday, November 5, 2026, about 46 days away. Earnings reports often cause large overnight gaps, so many traders manage risk around the date. The date can shift until the company officially confirms it.
The CHRS Live Alerts panel on this page streams real-time unusual volume (RVOL), momentum, halt and 200-EMA alerts from our scanner the moment they fire. Our scanner has flagged CHRS 23 times in the last 30 days.
CHRS (Coherus Oncology, Inc. Common Stock) trades on XNAS, with a market cap of about $209M in the Biological Products, (No Diagnostic Substances) sector.
That depends on your strategy and risk. Day traders look for volume, volatility and a clear trend. Use the live chart, RVOL alerts and 200-EMA context on this page to judge CHRS for yourself. This is not investment advice.
Live data from TheDesperateTrader scanner. Not investment advice.
$CHRS discussion
Sign in to ask a question or join the discussion.